Status:
COMPLETED
The Effects of a Glutathione Precursor (FT061452),on Serum and Intracellular Glutathione Levels
Lead Sponsor:
Charles Drew University of Medicine and Science
Conditions:
Oxidative Stress
Eligibility:
All Genders
30-65 years
Phase:
PHASE1
Brief Summary
Glutathione is a powerful protective substance found within every cell in the body. It has been shown that glutathione levels go down as a person gets older, which makes a person more likely to get he...
Detailed Description
Glutathione (gamma-glutamyl-cysteine-glycine; GSH) is a powerful antioxidant found within every cell. GSH is predominantly known to protect the cells from damage caused by free radicals. The concentra...
Eligibility Criteria
Inclusion
- Subjects will be healthy male or female, 30 to 65 years of age.
- Subjects must have a BMI between 20 and 35.
- Subjects must be able to provide informed consent after risks and benefits have been explained.
- Subjects must be non-smoking (defined as a subject who has not smoked for ≥ 6 months), and must agree to abstain from caffeine 72 hours prior to study day.
- Subjects are in generally good health, based on pre-study medical history, physical examination and routine laboratory tests.
- Subjects have, in the Investigator's opinion, no clinically significant disease and/or clinically significant abnormal laboratory values as determined by the Investigator based on medical history, physical examination, or laboratory evaluations conducted at the screening visit or on admission to the clinic.
Exclusion
- Subjects who have a history of drug or alcohol abuse within 6 months of study screening, as determined by the Investigator.
- Subjects who have participated in any investigational trial within 30 days or six half-lives of the test drug's biologic activity, whichever is longer, before the start of the study (time of first dose).
- Subjects who have clinically significant medical or psychiatric illnesses currently or within 30 days of start of study (time of first dose), as determined by 3. the Investigator.
- Subjects who have had symptoms of any significant acute illness within 30 days prior to the start of study (time of first dose),
- Subjects who have any condition that interferes with their ability to understand or comply with the requirements of the study.
- Females who are pregnant or nursing or have a high likelihood of becoming pregnant during the study.
Key Trial Info
Start Date :
December 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2011
Estimated Enrollment :
24 Patients enrolled
Trial Details
Trial ID
NCT01251315
Start Date
December 1 2010
End Date
June 1 2011
Last Update
April 14 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Charles Drew University
Los Angeles, California, United States, 90059